home / stock / fwbi / fwbi news

FWBI News and Press, First Wave BioPharma Inc. From 12/27/23

Stock Information
Company Name: First Wave BioPharma Inc.
Stock Symbol: FWBI
Market: NASDAQ
Menu
FWBI FWBI Quote FWBI Short FWBI News FWBI Articles FWBI Message Board
Get FWBI Alerts

News, Short Squeeze, Breakout and More Instantly...
FWBI - 24/7 Market News Lunch Break 27 Dec 2023

2023-12-27 12:23:36 ET DENVER, Colo., Dec. 27, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; First Wave BioPharma Inc (NASDAQ: FWBI), Coherus BioSciences Inc (NASDAQ: CHRS), Cingulate Inc (NASDAQ...
FWBI - First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds Priced

BOCA RATON, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (“First Wave BioPharma” or the “Company”) (NASDAQ: FWBI), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal ...

FWBI - Making Waves- 24/7 Market News Snapshot 27 Dec 2023

2023-12-27 09:57:20 ET DENVER, Colo., Dec. 27, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; First Wave BioPharma Inc (NASDAQ: FWBI), Coherus BioSciences Inc (NASDAQ: CHRS), Opthea Ltd (NASDAQ: OPT), Ci...

FWBI - Cytokinetics, Burford Capital, Cipher Mining among premarket gainers' pack

2023-12-27 08:27:59 ET First Wave BioPharma FWBI +107% on plans to sell niclosamide program . Cingulate ( CING ) +89% . Cytokinetics CYTK +53% on positive Phase 3 data for heart disease therapy . Jet.AI ( JTAI ) +38% . Cohe...
FWBI - Listing Plans on Adding by Streamlining

2023-12-27 07:49:33 ET DENVER, Colo., Dec 27, 2023 ( www.247marketnews.com )- First Wave BioPharma, Inc. (NASDAQ: FWBI) stated, this morning, that it entered into a non-binding term sheet to sell its Niclosamide program for the treatment of inflammatory bowel diseases (IBD), which will ...

FWBI - First Wave BioPharma surges on plans to sell niclosamide program

2023-12-27 07:43:36 ET More on First Wave BioPharma First Wave BioPharma files for stock and warrants offering, size not disclosed First Wave BioPharma CFO discloses sale of 1,676 shares Seeking Alpha’s Quant Rating on First Wave BioPharma Historical e...

FWBI - First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program

BOCA RATON, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointe...
FWBI - First Wave BioPharma Announces Entry into Term Sheet for Business Combination with ImmunogenX Establishing a Leading Late-Stage GI-Focused Biopharmaceutical Company

Phase 3-ready latiglutenase, a targeted oral biotherapeutic for celiac disease, will expand First Wave BioPharma’s late-stage gastrointestinal (GI) disease clinical pipeline A concurrent institutional investment and a strategic U.S. license agreement with a global pharmaceutical ...

FWBI - First Wave BioPharma approves a 1-for-20 reverse stock split

2023-12-14 11:23:20 ET More on First Wave BioPharma First Wave BioPharma files for stock and warrants offering, size not disclosed First Wave BioPharma CFO discloses sale of 1,676 shares For further details see: First Wave BioPharma approves a 1-for-20 reverse st...

FWBI - First Wave BioPharma Announces 1-for-20 Reverse Stock Split and Results of the Special Meeting of Stockholders

BOCA RATON, Fla., Dec. 14, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma,” “First Wave” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic the...
Previous 10 Next 10